Linda Thorp
Nurse Practitioner · Mansfield, PANPI 1184213597
Payments from drug & device makers
Across 66 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$240
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$142
- Pfizer$106
- Johnson & Johnson$78
- Novo Nordisk$70
- Dexcom, Inc.$63
- plus $491 from 20 others
What the payments were for
- Food & beverage$1,190100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 13 | $240 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $142 |
| Pfizer | 6 | $106 |
| Johnson & Johnson | 6 | $78 |
| Novo Nordisk | 3 | $70 |
| Dexcom, Inc. | 3 | $63 |
| GSK | 4 | $60 |
| AbbVie | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $38 |
| Amgen | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Alkermes, Inc. | 1 | $26 |
| AstraZeneca | 2 | $24 |
| CMP Pharma, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Organon | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
How this compares
$1,190 in reported general payments places this provider in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $163,297 |
| OzempicSemaglutide | 64 | $95,871 |
| JanuviaSitagliptin Phosphate | 41 | $45,217 |
| FarxigaDapagliflozin Propanediol | 52 | $37,952 |
| XareltoRivaroxaban | 54 | $34,837 |
| TrulicityDulaglutide | 21 | $33,683 |
| MounjaroTirzepatide | 22 | $28,411 |
| JardianceEmpagliflozin | 15 | $22,340 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $20,878 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $17,955 |
| Spiriva RespimatTiotropium Bromide | 27 | $17,783 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $12,141 |
| EntrestoSacubitril/Valsartan | 14 | $11,483 |
| InvokanaCanagliflozin | 16 | $9,049 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $5,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $163,297184 claims |
| Novo NordiskOzempic | $70 | $95,87164 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $240 | $62,09443 claims |
| MerckJanuvia | $13 | $45,21741 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $26 | $45,01953 claims |
| Johnson & JohnsonXarelto, Invokana | $78 | $43,88670 claims |
| AstraZenecaFarxiga | $24 | $37,95252 claims |
| GSKBreo Ellipta, Anoro Ellipta, Incruse Ellipta | $60 | $37,02479 claims |
| AbbVieSynthroid | $41 | $1,50346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Mansfield
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.